Research programme: oligonucleotides - BioNucleon

Drug Profile

Research programme: oligonucleotides - BioNucleon

Alternative Names: BN 210

Latest Information Update: 01 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioNucleon
  • Class Oligonucleotides
  • Mechanism of Action HDGFRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Lung cancer; Neuroblastoma
  • Research Colorectal cancer; Liver cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 30 Sep 2016 Early research in Colorectal cancer in Italy (unspecified route)
  • 30 Sep 2016 Early research in Liver cancer in Italy (unspecified route)
  • 30 Sep 2016 Early research in Malignant melanoma in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top